Ardsley Advisory Partners’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-580,000
| Closed | -$16.6M | – | 141 |
|
|
2024
Q2 | $16.6M | Buy |
580,000
+86,600
| +18% | +$2.48M | 2.44% | 7 |
|
|
2024
Q1 | $14.4M | Buy |
493,400
+191,400
| +63% | +$5.59M | 2.07% | 12 |
|
|
2023
Q4 | $10.2M | Sell |
302,000
-8,000
| -3% | -$270K | 1.57% | 14 |
|
|
2023
Q3 | $9.51M | Buy |
+310,000
| New | +$9.51M | 2.12% | 11 |
|
|
2022
Q4 | – | Sell |
-170,000
| Closed | -$9.04M | – | 112 |
|
|
2022
Q3 | $9.04M | Buy |
170,000
+35,000
| +26% | +$1.86M | 2.02% | 14 |
|
|
2022
Q2 | $7.87M | Buy |
135,000
+35,000
| +35% | +$2.04M | 1.3% | 16 |
|
|
2022
Q1 | $7.63M | Buy |
+100,000
| New | +$7.63M | 1.27% | 24 |
|